相关实验视频

Updated: Jan 16, 2026

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

通过传统的亚洲抗糖尿病营养药调节基因表达:对潜在影响的审查

Katrin Roosita¹, Karina Rahmadia Ekawidyani¹, Rosyanne Kushargina²

¹Department of Community Nutrition, Faculty of Human Ecology, IPB University, Bogor, Indonesia.

Asia Pacific journal of clinical nutrition

|October 2, 2025

概括

传统的亚洲营养保健品通过改善葡萄糖平衡和减少氧化应激,在治疗2型糖尿病 (T2DM) 中表现有前途. 需要进一步的临床试验来确认它们作为抗糖尿病剂的治疗潜力.

科学领域:

营养科学营养科学
药理学药理学是指药理学的学科.
生物化学生物化学

背景情况:

2型糖尿病 (T2DM) 是一个日益严重的全球健康问题.
传统的营养药,特别是来自亚洲的,正在研究它们的抗糖尿病潜力.
这些天然化合物可能为T2DM及其并发症提供治疗效益.

研究的目的:

审查具有抗糖尿病性质的传统营养药,重点关注亚洲来源.
检查这些营养保健品对与T2DM相关的基因表达的抗氧化作用.
探索它们在治疗糖尿病中的作用机制.

主要方法:

在主要数据库 (PubMed,Scopus,Science Direct) 进行了文献搜索.
关键词包括"营养药"",抗糖尿病"",草药"",亚洲"和相关术语.
搜索的重点是临床,临床前和动物研究,调查抗糖尿病机制.

主要成果:

印度尼西亚的草药饮料和各种亚洲植物含有生物活性化合物 (例如黄素,氨酸),具有已证明的抗糖尿病作用.
这些化合物可以减少与T2DM相关的高血糖症,氧化应激和肥胖.
观察到对β细胞功能,胰岛素信号和抗氧化剂通路中的基因表达的调节.

结论:

传统的亚洲营养药物为T2DM预防和管理提供了有希望的替代品.
它们的生物活性化合物影响了与糖尿病相关的关键途径.
严格的双盲随机临床试验是必要的,以验证这些发现.

关键词:

亚洲传统的营养保健品.抗氧化剂抗氧化剂是一种抗氧化剂.基因表达的基因表达方式氧化应激是一种氧化应激.2型糖尿病是什么?

更多相关视频

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Extraction and Analysis of Taiwanese Green Propolis

Extraction and Analysis of Taiwanese Green Propolis

Published on: January 7, 2019

相关概念视频

Hormones Regulating Blood Glucose

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...